SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
Considering that COVID-19 could adversely affect cancer patients, several countries have prioritized this highly susceptible population for vaccination. Thus, rapidly generating evidence on the efficacy of SARS-CoV-2 vaccination in the subset of patients with cancer under active therapy is of paramo...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/11/2796 |
| _version_ | 1797493819334197248 |
|---|---|
| author | Evangelos Terpos Michalis Liontos Oraianthi Fiste Flora Zagouri Alexandros Briasoulis Aimilia D. Sklirou Christos Markellos Efthymia Skafida Alkistis Papatheodoridi Angeliki Andrikopoulou Konstantinos Koutsoukos Maria Kaparelou Vassiliki A. Iconomidou Ioannis P. Trougakos Meletios-Athanasios Dimopoulos |
| author_facet | Evangelos Terpos Michalis Liontos Oraianthi Fiste Flora Zagouri Alexandros Briasoulis Aimilia D. Sklirou Christos Markellos Efthymia Skafida Alkistis Papatheodoridi Angeliki Andrikopoulou Konstantinos Koutsoukos Maria Kaparelou Vassiliki A. Iconomidou Ioannis P. Trougakos Meletios-Athanasios Dimopoulos |
| author_sort | Evangelos Terpos |
| collection | DOAJ |
| description | Considering that COVID-19 could adversely affect cancer patients, several countries have prioritized this highly susceptible population for vaccination. Thus, rapidly generating evidence on the efficacy of SARS-CoV-2 vaccination in the subset of patients with cancer under active therapy is of paramount importance. From this perspective, we launched the present prospective observational study to comprehensively address the longitudinal dynamics of immunogenicity of both messenger RNA (mRNA) and viral vector-based vaccines in 85 patients treated with immune checkpoint inhibitors (ICIs) for a broad range of solid tumors. Despite the relatively poor humoral responses following the priming vaccine inoculum, the seroconversion rates significantly increased after the second dose. Waning vaccine-based immunity was observed over the following six months, yet the administration of a third booster dose remarkably optimized antibody responses. Larger cohort studies providing real-world data with regard to vaccines effectiveness and durability of their protection among cancer patients receiving immunotherapy are an increasing priority. |
| first_indexed | 2024-03-10T01:25:26Z |
| format | Article |
| id | doaj.art-07d541aa94b44f9e9fd5d4e9fd3e9abb |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T01:25:26Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-07d541aa94b44f9e9fd5d4e9fd3e9abb2023-11-23T13:51:16ZengMDPI AGCancers2072-66942022-06-011411279610.3390/cancers14112796SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint InhibitionEvangelos Terpos0Michalis Liontos1Oraianthi Fiste2Flora Zagouri3Alexandros Briasoulis4Aimilia D. Sklirou5Christos Markellos6Efthymia Skafida7Alkistis Papatheodoridi8Angeliki Andrikopoulou9Konstantinos Koutsoukos10Maria Kaparelou11Vassiliki A. Iconomidou12Ioannis P. Trougakos13Meletios-Athanasios Dimopoulos14Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceSection of Cell Biology and Biophysics, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceSection of Cell Biology and Biophysics, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, GreeceSection of Cell Biology and Biophysics, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceConsidering that COVID-19 could adversely affect cancer patients, several countries have prioritized this highly susceptible population for vaccination. Thus, rapidly generating evidence on the efficacy of SARS-CoV-2 vaccination in the subset of patients with cancer under active therapy is of paramount importance. From this perspective, we launched the present prospective observational study to comprehensively address the longitudinal dynamics of immunogenicity of both messenger RNA (mRNA) and viral vector-based vaccines in 85 patients treated with immune checkpoint inhibitors (ICIs) for a broad range of solid tumors. Despite the relatively poor humoral responses following the priming vaccine inoculum, the seroconversion rates significantly increased after the second dose. Waning vaccine-based immunity was observed over the following six months, yet the administration of a third booster dose remarkably optimized antibody responses. Larger cohort studies providing real-world data with regard to vaccines effectiveness and durability of their protection among cancer patients receiving immunotherapy are an increasing priority.https://www.mdpi.com/2072-6694/14/11/2796SARS-CoV-2vaccinationcancerimmune checkpoint inhibitorsimmunotherapy |
| spellingShingle | Evangelos Terpos Michalis Liontos Oraianthi Fiste Flora Zagouri Alexandros Briasoulis Aimilia D. Sklirou Christos Markellos Efthymia Skafida Alkistis Papatheodoridi Angeliki Andrikopoulou Konstantinos Koutsoukos Maria Kaparelou Vassiliki A. Iconomidou Ioannis P. Trougakos Meletios-Athanasios Dimopoulos SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition Cancers SARS-CoV-2 vaccination cancer immune checkpoint inhibitors immunotherapy |
| title | SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition |
| title_full | SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition |
| title_fullStr | SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition |
| title_full_unstemmed | SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition |
| title_short | SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition |
| title_sort | sars cov 2 neutralizing antibodies kinetics postvaccination in cancer patients under treatment with immune checkpoint inhibition |
| topic | SARS-CoV-2 vaccination cancer immune checkpoint inhibitors immunotherapy |
| url | https://www.mdpi.com/2072-6694/14/11/2796 |
| work_keys_str_mv | AT evangelosterpos sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT michalisliontos sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT oraianthifiste sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT florazagouri sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT alexandrosbriasoulis sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT aimiliadsklirou sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT christosmarkellos sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT efthymiaskafida sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT alkistispapatheodoridi sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT angelikiandrikopoulou sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT konstantinoskoutsoukos sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT mariakaparelou sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT vassilikiaiconomidou sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT ioannisptrougakos sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition AT meletiosathanasiosdimopoulos sarscov2neutralizingantibodieskineticspostvaccinationincancerpatientsundertreatmentwithimmunecheckpointinhibition |